164.99MMarket Cap
LossP/E TTM
Key Figures
11.600Open
11.600High
3.18KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.02%Turnover Ratio
11.530Prev. Close
11.180Low
33.83KTurnover
LossP/E Static
1.38P/B
0.00%Div Yield TTM
-58.83%ROA
55.89052wk High
0.16Volume Ratio
-83.58MNet Profit
14.42MShares
-11.6804EPS TTM
3.02Beta
-87.78%ROE
5.20452wk Low
3.64%Amplitude
100.00%Gross Margin
164.99MMarket Cap
-2.91Reward/Risk
5.58%Risk Rate
Currency: USD Updated: 2026-07-23 Key Insights
Korro Bio Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 139 out of 386 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 19.56.In the medium term, the stock price is expected to trend down.The company has shown weak stock market performance over the past month, in line with its weak fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Korro Bio Inc Highlights
StrengthsRisks
Korro Bio Inc News
More news coming soon, stay tuned...
Earnings Forecast
Strong Buy
Buy
Hold
Sell
Strong Sell
Ionis Pharmaceuticals Inc
IONS
26
Indicators
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Korro Bio Inc Info
Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.
Ticker SymbolKRRO
CompanyKorro Bio Inc
CEODr. Ram Aiyar, Ph.D.
Websitehttps://www.korrobio.com/
Shareholders
FAQs
What is the current price of Korro Bio Inc (KRRO)?
The current price of Korro Bio Inc (KRRO) is 11.51.
What is the symbol of Korro Bio Inc?
The ticker symbol of Korro Bio Inc is KRRO.
What is the 52-week high of Korro Bio Inc?
The 52-week high of Korro Bio Inc is 55.89.
What is the 52-week low of Korro Bio Inc?
The 52-week low of Korro Bio Inc is 5.20.
What is the market capitalization of Korro Bio Inc?
The market capitalization of Korro Bio Inc is 166.00M.
Is Korro Bio Inc (KRRO) currently rated as Buy, Hold, or Sell?
According to analysts, Korro Bio Inc (KRRO) has an overall rating of Buy, with a price target of 19.56.
What is the Earnings Per Share (EPS TTM) of Korro Bio Inc (KRRO)?
The Earnings Per Share (EPS TTM) of Korro Bio Inc (KRRO) is -12.48.
